Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Therapy Resistance in Prostate Cancer
Mechanisms and Insights
- 1st Edition, Volume 20 - October 24, 2023
- Editor: Hisham Bahmad
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 6 0 3 2 - 5
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 6 0 3 3 - 2
Therapy Resistance in Prostate Cancer: Mechanisms and Insights, Volume 20 highlights the main mechanisms that are responsible for therapy resistance in PCa allowing researche… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTherapy Resistance in Prostate Cancer: Mechanisms and Insights, Volume 20 highlights the main mechanisms that are responsible for therapy resistance in PCa allowing researchers and clinicians to have a synopsis of current options and therapies that can be proposed to overcome resistance. Understanding the mechanisms responsible for chemotherapy resistance helps researchers all over the world delve deeper into the pathways behind this resistance and potentially discover new therapeutic targets for PCa. Prostate cancer (PCa) is among the most diagnosed cancers in men worldwide, as well as one of the most common causes of cancer-related deaths.
Despite the advances in treatment, the disease remains associated with poor survival and resistance to cytotoxic and targeted therapies.
- Tackles the topic of resistance from a broader perspective, including, but not limited to, the role of the extracellular matrix and cancer stem cells in therapy resistance
- Creates understanding on how to develop novel therapies that specifically target CSCs to eliminate the regenerating capacity of the tumor and overcome therapy resistance
- Helps in identifying novel molecular biomarkers and potential therapeutic targets pertaining to the tumor microenvironment to overcome therapy resistance
- Provides a general view of the main pathways involved in PCa progression that will aid in understanding the mechanisms responsible for chemotherapy resistance
Researchers and healthcare personnel in the field of prostate cancer, Urologists, Hemato-oncologists, genitourinary pathologists.Medical students and resident physicians and fellows interested in genitourinary medicine, and patients with prostate cancer
- Cover image
- Title page
- Table of Contents
- Copyright
- Cover Image Insert
- Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy”
- About the Series Editor
- Aims and Scope of Volume
- About the Volume Editor
- Preface
- Contributors
- Chapter 1 Prostate gland anatomy and hormonal factors contributing to cancer development
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- Embryologic development of the prostate gland
- Anatomy of the prostate
- Cellular anatomy
- Hormones and receptors of the prostate
- Conclusion
- References
- Chapter 2 Role of tumor microenvironment in prostate cancer therapy resistance
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- PCa therapy and resistance
- Types of microenvironments in PCa
- Conclusion
- References
- Chapter 3 Androgen receptor-dependent mechanisms mediating therapy resistance in prostate cancer
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- Androgen receptor
- Role of androgen receptor in prostate cancer
- Androgen receptor-dependent mechanisms of therapy resistance
- Crosstalk between androgen receptor axis and other signaling pathways
- Conclusion
- References
- Chapter 4 Epigenetic changes driving therapy resistance in prostate cancer
- Abstract
- Conflict of interest
- Introduction
- Types of epigenetics in prostate cancer
- Epigenetic modulators in the treatment of PCa
- Conclusion
- References
- Chapter 5 Role of cancer stem cells in prostate cancer therapy resistance
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- PCSCs
- PCSCs and therapy resistance
- Conclusion
- References
- Chapter 6 Resistance to taxane chemotherapies in prostate cancer
- Abstract
- Conflict of interest
- Introduction
- History and molecular mechanisms of taxane action in cancer therapy
- Molecular mechanisms of taxane resistance and corresponding overcoming strategies
- Conclusion
- References
- Chapter 7 Resistance of prostate cancer to topoisomerase inhibitors
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- DNA topoisomerases
- Topoisomerase I inhibitors
- Topoisomerase II inhibitors
- Role of topoisomerase inhibitors in prostate cancer treatment
- Resistance of prostate cancer to topoisomerase I inhibitors
- Resistance of prostate cancer to topoisomerase II inhibitors
- Conclusion
- References
- Chapter 8 Resistance of prostate cancer to kinase inhibitors
- Abstract
- Conflict of interest
- Introduction
- EGFR signaling pathway
- EGFR/HER2 signaling pathway
- PI3K pathway
- VEGF pathway
- FLT3 pathway
- Serine/threonine kinase pathway
- c-Kit pathway
- Src kinase pathway
- BCR-ABL pathway
- CSF1R pathway
- Conclusion
- References
- Chapter 9 Radioresistance mechanisms in prostate cancer
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- What are the radioresistance mechanisms?
- Tumor microenvironment
- Clinical implications of radioresistance mechanisms
- Radio-adaptive changes leading to resistance
- Conclusion
- References
- Chapter 10 Immunotherapeutic strategies and immunotherapy resistance in prostate cancer
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- Vaccines
- Single-agent ICIs
- ICI combinations
- Future directions
- Conclusion
- References
- Chapter 11 Overcoming resistance in prostate cancer with targeted and small molecule-based therapies
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- Androgen-targeted therapies
- Microtubule inhibitors
- PSMA inhibitors
- PARP inhibitors
- Conclusion
- References
- Chapter 12 Novel treatment strategies to overcome resistance in prostate cancer
- Abstract
- Acknowledgments
- Conflict of interest
- Introduction
- Nonmetastatic castration-resistant prostate cancer
- Metastatic castration-resistant prostate cancer
- Metastatic CRPC (patients previously exposed to an ARPI but not docetaxel)
- Metastatic CRPC (patients previously exposed to both an ARPI and docetaxel)
- Metastatic CRPC (aggressive-variant prostate cancer includes liver metastases, lytic bone lesions, rapid progression on ADT)
- Conclusion
- References
- Index
- No. of pages: 340
- Language: English
- Edition: 1
- Volume: 20
- Published: October 24, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780443160325
- eBook ISBN: 9780443160332
HB
Hisham Bahmad
Dr. Bahmad is a physician scientist with more than 8 years of experience in basic, clinical, and translational research (2014-Present), mainly focusing on prostate, bladder, and brain tumors. His research work concentrates on understanding cancer progression and isolating and therapeutically targeting cancer stem cells in solid tumors (such as prostate cancer among others) which are believed to be responsible for therapy resistance and tumor recurrence. He has so far published more than 100 peer-reviewed papers and book chapters in well-reputable journals mainly related to cancer stem cells and overcoming therapy resistance in various tumors. Dr. Bahmad has an MBA degree in Healthcare Management from West Texas A&M University and is currently pursuing his Pathology Residency at Mount Sinai Medical Center of Florida.
Affiliations and expertise
Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL, USA